Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
about
Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinomaAntiangiogenic mechanisms and factors in breast cancer treatmentEGFR Signaling in Liver DiseasesSystemic therapy of hepatocellular carcinoma: current status and future perspectivesTargeted therapy for hepatocellular carcinoma: novel agents on the horizonAngiogenesis Inhibitors for the Treatment of Hepatocellular CarcinomaCombination treatment including targeted therapy for advanced hepatocellular carcinomaHepatocellular carcinoma: Where there is unmet needMolecular classification and novel targets in hepatocellular carcinoma: recent advancementsNonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells.Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinomaEfficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma.Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials.Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro.Liver cancer: Targeted future optionsV-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.Novel therapeutic strategies for targeting liver cancer stem cells.Targeting metastatic upper gastrointestinal adenocarcinomasCediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.Targeted therapy in hepatocellular carcinomaCan we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a reviewHCC and angiogenesis: possible targets and future directionsMixed response and time-to-event endpoints for multistage single-arm phase II designTargeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implicationsDownregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells.A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts.Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.
P2860
Q24316017-302BE6A2-C7B1-4EBD-BE8D-488286908CC8Q26751226-281E79DD-64C3-4BB6-B210-E631D75F2CC9Q26771265-69484DF3-04B6-4D60-B83D-68558059834BQ26865844-CEAFBFC2-1C52-41A2-B1BB-1E545BABACD0Q27002288-235F947E-3E4D-4938-B56C-F3EBC2626BF9Q28075305-FD136B1B-66BF-4D5F-BFBC-211BFB941C1FQ28077738-175C7CF5-97F8-4403-B64B-CD4F43E6A5A0Q28084046-16706400-69A2-44D8-93D5-5F5325B7B573Q28383646-E4C36285-9372-480A-87A2-1654D410A1FEQ30234736-A2E41FE6-DFB5-4DE0-8F88-E0A7E75FEA4CQ33419633-71C0E645-670A-47B0-97F2-3754C67E50FAQ33660974-149D9899-8819-48B7-8CF3-4EC0D12C76B6Q33742856-7D6A590F-649B-4352-93D9-BAC54839BE95Q33747394-F4B9F67B-0E07-4C5D-871B-3DE8738EFA42Q33802709-8D7471EF-D472-4367-A7D0-505908C1E3B5Q34048813-6C20C701-DF1A-4D3E-B1F6-8A4B4E79FBF9Q34131801-44735B79-C51D-4E52-A5DE-907E7C631E4FQ34168811-E583FA76-74E1-481F-A482-BFFA768AC9FAQ34197835-1E2C17FB-DC3A-4762-98A7-7B929CD8AB5CQ34409128-7A554D5A-C0A4-4826-A29C-54C5F51B5C1AQ34504649-2FABB4B2-DBE1-4EF5-B1B4-0C93E5135E5FQ34531474-9649070C-F9AC-4AF7-AE6D-8BD7EFA1F2B8Q34548464-DE439D57-4BF1-42A5-A1CF-9F9EEE8F2CA4Q34695180-90441877-D834-4320-840D-6334EE09AB6DQ34733478-4BA86575-B873-4BF8-AB74-397D38F1E434Q34940971-B547882C-7C03-47F1-9497-99C168765087Q35000785-56A09EC5-B32E-453E-A433-B718D15CD1F0Q35078518-8D570326-E690-440C-9D72-725E99AA220DQ35207561-AA4B94AA-B986-45C1-8E66-4CAF2C3DF723Q35230282-B2D184E4-3D62-44A2-8548-011FA4C6E1E1Q35501246-A26C3462-6F42-4768-9920-608392DC4333Q35541482-384E102C-DCFF-48E2-BFBC-C8D1A59BFB24Q35584543-3DC3A6BC-190F-4D4A-BE04-1DBD2FC98E03Q35698574-261E38A3-0BE7-4153-AB40-88ABB698D7E5Q35700578-BCE2E071-95C9-4E24-8441-2E94C573BAA9Q35759606-74E7C5F1-D697-41B5-89FD-ABB88D9AB268Q35856029-43EE7E1B-B24E-46E2-97F1-7E1DE5E6BB23Q35884134-BCD6A04B-C536-4F8C-A1D0-0446B15A6782Q35913461-764050DF-4950-4198-A7EE-46754EA1BE9BQ36182824-5F80BC7D-5346-48FC-8BD8-ACD9F6C80A4D
P2860
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase II trial of the combinat ...... nced hepatocellular carcinoma.
@ast
Phase II trial of the combinat ...... nced hepatocellular carcinoma.
@en
type
label
Phase II trial of the combinat ...... nced hepatocellular carcinoma.
@ast
Phase II trial of the combinat ...... nced hepatocellular carcinoma.
@en
prefLabel
Phase II trial of the combinat ...... nced hepatocellular carcinoma.
@ast
Phase II trial of the combinat ...... nced hepatocellular carcinoma.
@en
P2093
P921
P356
P1476
Phase II trial of the combinat ...... anced hepatocellular carcinoma
@en
P2093
Ahmed Kaseb
James Abbruzzese
Jeffrey S Morris
Katrina Glover
Marta Davila
Melanie B Thomas
Michiko Iwasaki
P304
P356
10.1200/JCO.2008.18.3301
P407
P577
2009-01-12T00:00:00Z